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Abstract
Background: Infections with certain human herpesviruses have been established as risk factors for some cancer types.
For example, Epstein-Barr Virus is considered a cause of Burkitt's lymphoma and other immunosuppression related
lymphomas, Hodgkin lymphoma, and nasopharyngeal cancer. Several other human herpesviruses have been linked to
cancers but the totality of evidence is inconclusive.
Methods: We conducted a systematic sub-study from within an ongoing case control study of adult black South Africans
to investigate the relationship between antibodies to six human herpesviruses and seven cancer groups that may be
caused by infectious agents. Subjects had incident cancers of the oral cavity(n = 88), the cervix(n = 53), the prostate(n =
66), Hodgkin lymphoma(n = 83), non-Hodgkin lymphoma(n = 80), multiple myeloma(n = 94) or leukaemia(n = 203). For
comparison, patients with other cancers(n = 95) or cardiovascular disease(n = 101) were randomly selected from within
the study. Patients were interviewed and their blood was tested for IgG antibodies against HSV-1, HSV-2, VZV, EBV-
EBNA, CMV and HHV-6 using enzyme linked immunosorbent assays. Because these viruses are highly prevalent in this
population, optical density results from the assays were used as an indirect, quantitative measure of antibody level.
Results: There was significant variation in the mean log antibody measures for HSV-2, VZV, CMV and HHV-6 between
the disease groups. However, none of the specific cancer groups had significantly higher mean log antibody measures for
any of the viruses compared to either control group. In a more detailed examination of seven associations between
cancers and herpesviruses for which there had been prior reports, two statistically significant associations were found:
a decreasing risk of myeloid leukaemia and an increasing risk of oral cancer with increasing tertiles of antibodies against
HHV-6 compared to all other patients (p-trend = 0.03 and 0.02, respectively). Odds ratios for the top tertile compared
to the bottom tertile were 0.58 (95%CI 0.3 – 1.0) for myeloid leukaemia and 2.21 (95% CI 1.1 – 4.3) for oral cancer.
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Conclusion: In this population, using these tests for IgG, neither mean antibody measure nor high antibody measure
against human herpesviruses 1–6 was strongly associated with any of the seven cancer groups. However, we may not
have had sufficient power to detect weak associations or associations with a sub-type of cancer if they were present.
Background
Infection with certain types of human herpesviruses has
been established as a cause of several cancers. These
include Epstein-Barr Virus (EBV) for Burkitt's lymphoma
and other immunosuppression related lymphomas,
Hodgkin lymphoma, and nasopharyngeal cancer [1]; and
human herpesvirus 8 (HHV-8) for Kaposi's sarcoma [2].
These cancers are rare responses to the presence of these
widespread viruses.
Several human herpesviruses have been linked to other
cancers although the totality of evidence is inconclusive.
For example herpes simplex virus type 1 (HSV-1) has been
associated with oral cancer[3] and herpes simplex virus
type 2 (HSV-2) with cervical cancer in women who are co-
infected with specific human papillomavirus types[4].
Human herpesvirus type 6 (HHV-6) has been linked to
Hodgkin lymphoma [5], acute myeloid leukaemia [6] and
oral cancer [7]. In addition it has been suggested that pros-
tate cancer [8] and multiple myeloma [9] may have infec-
tious causes.
Our group previously found that high antibody levels to
HHV8 are highly correlated to the diagnosis of Kaposi's
sarcoma [2]. We therefore designed a study to examine, in
a systematic way, antibody levels to six of the herpesvi-
ruses (HSV-1, HSV-2, Varicella Zoster (VZV), EBV,
cytomegalovirus (CMV) and HHV-6) in relation to seven
cancer groups for which there is some evidence of an
infectious cause (oral, cervical, prostate, Hodgkin lym-
phoma, non-Hodgkin lymphoma, multiple myeloma and
leukaemia). The study was part of a larger case-control
study of the causes of cancer in black South Africans,
which was conducted in public hospitals that treat cancer
in greater Johannesburg, South Africa [2,10]. Since most
human herpesviruses are highly prevalent, and PCR on
biopsy samples is unrealistic in this setting, we used quan-
titative measures of anti-human herpesvirus antibodies
from enzyme linked immunosorbent assays (ELISAs). In
addition we examined the relationships between demo-
graphic and lifestyle factors and antibody levels against




The study population has been described previously
[2,10]. Briefly, between March 1995 and February 1999
trained nurses interviewed adult black patients with newly
diagnosed cancer at tertiary government hospitals in
Johannesburg (Chris Hani-Baragwanath, Hillbrow, and
Johannesburg General Hospitals). A standard question-
naire, administered in the language of the patient (usually
an Nguni or Sotho group language), was used. Questions
were asked about socio-demographic factors and behav-
ioural characteristics including age, sex, birthplace, resi-
dence, level of education, tobacco and alcohol use, and
reproductive and lifetime sexual history.
Blood was collected from 84% of patients at the time of
interview and prior to commencing treatment. The
remainder were too ill, had collapsed veins, or refused
consent. All interviewed patients with oral cancer (n =
88), Hodgkin lymphoma (n = 83), non-Hodgkin lym-
phoma (n = 80), multiple myeloma (n = 94) and leukae-
mia (n = 203) and a random sample of subjects with
cervical (n = 53) and prostate cancer (n = 66) were
included in the study if they had provided a blood sam-
ple. Controls were from two groups of patients attending
the same hospitals: a group of patients with other cancers
(n = 95) and a group with cardiovascular diseases (n =
101). The controls were selected randomly within sex and
age bands, and frequency matched to the cancer cases as a
whole according to five-year age-groups and sex. Diag-
noses of cancer were established, where appropriate, by
histology, haematology, or cytology. The study was
approved by the Committee for Research on Human Sub-
jects (Medical) of the University of the Witwatersrand,
and informed consent was obtained from all patients.
Laboratory methods
After coagulation, specimens were centrifuged to obtain
serum. The serum specimens were aliquotted and stored
at -20° to -30°C. HIV testing was carried out by the Serol-
ogy Laboratory of the South African Institute for Medical
Research (now the National Health Laboratory Service),
using commercial ELISA kits. Early testing was for HIV-1
only; later testing for both HIV-1 and HIV-2. Patients with
borderline results were considered to be HIV negative.
Herpes virus antibody testing was done at the South Afri-
can National Institute for Virology (now the National
Institute for Communicable Diseases) from January to
April 2000. Throughout the testing period specimens were
kept at 4°C. The commercially available kits used were:
Eurogenetics for HSV-1, HSV-2 and CMV; Clark Laborato-
ries for VZV and EBV nuclear antigen-1(EBNA); and Pan-
Bio for HHV-6. These were selected followingInfectious Agents and Cancer 2006, 1:2 http://www.infectagentscancer.com/content/1/1/2
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apreliminary study which demonstrated good quantita-
tive performance with South African sera. The test for
EBNA IgG used "recombinant EBNA-1 antigen". All other
kits used unspecified antigens.
Patients' sera were randomly allocated to the 96-well
microplates to minimise potential bias due to systematic
differences between the plates or day on which the plates
were run. Each specimen was run in a single well. There
were a total of 12 plates for each assay and in general two
plates were run each day. Repeatability of each assay was
investigated through replicate measures on a pool of sera
samples with high antibody measures against each virus.
Test results were initially in optical density units which are
proportional to the concentration of antibody i.e. the
antibody titre. The CMV kit had a calibration curve giving
final results in antibody units/ml. The remaining kits con-
tained standards used to determine a cut-off for positivity.
Results are reported as ratios to the manufacturer's cut-off
value. Throughout this paper we use the general term
"antibody measure" to refer to the manufacturer's result,
regardless of whether it is in AU/ml or "times cut-off".
Statistical Analysis for the control samples
There were several potential sources of variability in each
assay such as antigen binding within or between plates,
washing conditions between binding steps and laboratory
conditions such as the temperature, humidity, and light.
For each of the herpesviruses the logarithm (log) antibody
measure was computed for the control pool and analysis
of variance was used to estimate the magnitude of the
components of variance for each of the sources of variabil-
ity.
Statistical Analysis of the Patient Data
To examine the relation between antibodies against the
human herpesviruses 1–6 and cancer the mean log anti-
body measures for each of the nine disease groups were
compared using analysis of variance. Least square mean
log antibody measures were calculated for each disease
group with adjustment for age, sex, HIV status, and the
day and the plate on which the assay was run. Paired com-
parisons were conducted between each cancer group and
each of the two control groups (other cancers and cardio-
vascular disease patients) with Bonferroni adjustments for
multiple comparisons. Where positive associations had
previously been found (see Introduction [1-7]), the spe-
cific hypotheses were investigated in more detail by com-
paring the specified cancer group to all the other patients
combined with respect to tertiles of log antibody measure.
Odds ratios were calculated using logistic regression with
adjustment for age, sex, HIV status and the day and the
plate on which the assay was run.
Since little is known about risk factors for infection with
human herpesviruses in this population, we examined the
relationship between antibody measure and a number of
socio-demographic variables using analysis of variance
with adjustment for each of these variables as well as can-
cer group, day of assay, and assay plate. Due to the
number of comparisons that were made these analyses
were examined at the 0.01 significance level.
All analyses were carried out using SAS statistical software
[11].
Results
In total 667 patients with the seven specific cancers of
interest were included in the study. A further 95 patients
with other types of cancer and 101 patients with cardio-
vascular diseases were included as control subjects.
Demographic characteristics of the study members are
shown in Table 1.
The results from the analysis of the control samples sug-
gested that for all assays (except for HSV-1 and HSV-2) the
most important source of systematic variation was the day
on which the plates were assayed, whereas for the HSV-1
and HSV-2 assays it was the plates themselves (data not
shown). As the plate and day on which each patient's sam-
ple was tested had been recorded, variation between days
and between plates was controlled for in the main analy-
ses by adjusting for these factors.
Crude adult prevalence rates in the study, determined
using the manufacturer's criteria for positivity, were: 99%
for HSV-1; 59% for HSV-2 (52% in males and 68% in
females); 97% for VZV; 96% for EBV (EBNA antigen);
99% for CMV; and 90% for HHV-6 (88% in males and
93% in females).
Associations with cancer types
There was statistically significant variation between the
nine disease groups in mean log antibody measure for
HSV-2 (p < 0.0001), VZV (p < 0.0001), CMV (p = 0.009)
and HHV-6 (p < 0.0001) (Figure 1). Patients with multi-
ple myeloma had lower mean log antibody measures for
almost all these herpesviruses compared to other patients.
When patients with multiple myeloma were excluded, sig-
nificant heterogeneity in mean log antibody measures
between the eight remaining disease groups was still
present for HSV-2 (p = 0.0007) and HHV-6 (p = 0.004).
In paired comparisons (with Bonferroni adjustments),
patients with multiple myeloma had significantly lower
mean log IgG antibody measures for the response to VZV,
CMV and HHV-6 compared to patients in the 'other can-
cer' group (p < 0.0001, 0.02 and p < 0.0001 respectively)







































































































































Table 1: Demographic characteristics of patients by disease group
Cancer group
Lip, oral cavity and pharynx Cervix Prostate Hodgkin lymphoma non-Hodgkin lymphoma Multiple myeloma Leukaemia Other cancers1 Cardiovascular disease
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Males 64 (73) 0 (0) 66 (100) 46 (55) 45 (56) 52 (55) 92 (45) 45 (47) 45 (45)
Females 24 (27) 53 (100) 0 (0) 37 (45) 35 (44) 42 (45) 111 (55) 50 (53) 56 (55)
Age <35 yrs 6 (7) 15 (28) 0 (0) 33 (40) 22 (28) 5 (5) 57 (28) 23 (24) 17 (17)
Age 35–49 yrs 17 (19) 12 (23) 6 (9) 35 (43) 25 (31) 23 (24) 54 (27) 26 (27) 29 (29)
Age 50+ yrs 65 (74) 26 (49) 60 (91) 15 (18) 33 (41) 66 (70) 92 (45) 46 (48) 55 (55)
HIV +ve 3 (3) 5 (9) 1 (2) 9 (11) 18 (23) 4 (4) 8 (4) 6 (6) 11 (11)
Total 88 (100) 53 (100) 66 (100) 83 (100) 80 (100) 94 (100) 203 (100) 95 (100) 101 (100)
1Includes cancers of the digestive organs, respiratory organs, bone, skin, soft tissue, breast, female and male genital organs, bladder, brain, thyroid and of unspecified sites.Infectious Agents and Cancer 2006, 1:2 http://www.infectagentscancer.com/content/1/1/2
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with cardiovascular diseases (p = 0.01, 0.0003 and
<0.0001 respectively). Because of their systematically
lower antibody measures, multiple myeloma patients
were excluded from further analyses. Patients with non-
Hodgkin lymphoma had significantly lower mean log
antibody measures in response to HSV-2 compared to the
non-cancer patients (p = 0.004). None of the specific can-
cer groups had significantly higher mean log antibody
measures for any of the viruses compared to either control
group.
To further investigate the positive associations reported in
previous studies (EBV and Hodgkin lymphoma; EBV and
non-Hodgkin lymphoma; HSV-1 and oral cancer; HSV-2
and cervical cancer; HHV-6 with oral cancer, Hodgkin
lymphoma and acute myeloid leukaemia) the log anti-
body measures were divided into tertiles according to the
levels in allpatientsexcluding those with multiple mye-
loma. The control group was defined in this way for these
analyses because in general mean antibody levels did not
vary significantly across disease groups after exclusion of
subjects with multiple myeloma (Figure 1), and including
more patients increased the power of these analyses. Only
oral cancer showed a statistically significant trend of risk
with increasing HHV-6 tertiles (p = 0.02), odds ratio for
the top tertile compared to all other subjects = 2.21 (95%
CI 1.1 – 4.3) (Table 2). All the oral cancer patients were
positive for HHV-6 antibodies by the manufacturer's cut-
off. Only two subjects had undifferentiated nasopharyn-
geal cancer so it was not possible to investigate the rela-
tionship between this sub-type of oral cancers and EBV.
Neither was it possible to separate acute myeloid leukae-
mias from chronic myeloid leukaemias with the informa-
tion that was available, but there was some evidence of a
decreasing trend in risk of myeloid leukaemia with
increasing tertiles of HHV-6 (p = 0.03); odds ratio for the
top tertile compared to all other subjects = 0.58 (95% CI
0.3 – 1.0).
Distribution of mean log antibody measures (and 95% CI) by disease group for herpesviruses 1–6 Figure 1
Distribution of mean log antibody measures (and 95% CI) by disease group for herpesviruses 1–6.Infectious Agents and Cancer 2006, 1:2 http://www.infectagentscancer.com/content/1/1/2
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Association with age, sex and socio-demographic factors
Possible determinants of high antibody measures to these
herpesviruses, such as age and sex and socio-demographic
factors, were investigated in an analysis of variance using
data from all the patients except those with multiple mye-
loma (Table 3). No risk factors were identified as signifi-
cantly influencing high log antibody measures in
response to HSV-1. For HSV-2 mean log antibody meas-
ures increased with age (p-trend = 0.003), were higher in
women (p < 0.0001), increased with number of sexual
partners (p-trend = 0.01) and were lower in single people
(p-heterogeneity = 0.005). No statistically significant
associations were found for VZV, or EBV-EBNA. Mean log
antibody measure for response to CMV increased signifi-
cantly with age (p-trend = 0.006) and was also higher in
females than in males (p < 0.0001). Similarly, the mean
log antibody measure for HHV-6 antibodies was signifi-
cantly higher in females than males (p = 0.0002).
Discussion
Herpesvirus infections are highly prevalent in human
populations. They usually produce transient illness or
inapparent infection and remain latent in the host. In gen-
eral, re-activation of the latent infection, re-infection, or
viral persistence will cause the established IgG antibody
levels to rise. In Burkitt's lymphoma it has been shown
that raised levels of IgG were present months before clin-
ical onset [12]. Antibodies to HHV-8 are also found many
months prior to the diagnosis or Kaposi's sarcoma [13]
and the diagnosis is highly correlated to high HHV-8 anti-
body levels [2]. It is therefore reasonable to speculate that
raised antibody levels to other viruses may be associated
with the development of other cancers.
We conducted a systematic study of the relationship
between antibodies against human herpesviruses 1–6 and
seven cancer groups in adult black South Africans. Our
results suggest that, in this population, neither mean
ELISA IgG antibody measure to the antigens used nor high
antibody measures against these six human herpesviruses
were strongly associated with any of the seven cancer
groups. Although we do not think that the variability in
the quantitative assay results concealed any strong associ-
ations, we may not have had sufficient power to detect
weak associations (for example, odds ratios <2.0) or asso-
ciations with a sub-type of cancer if they were present.
Though there was no evidence of a significant association
between high EBV-EBNA antibody measure and non-
Hodgkin lymphoma or Hodgkin lymphoma, EBV may be
a causative factor of certain types of lymphomas only,
including Burkitt's lymphoma and some immunosupres-
sion associated lymphomas [1]. As mentioned above, the
current study was not powered to detect associations in
Table 2: Odds ratios (OR) and 95% confidence intervals (CI) for specific cancers1 versus all other subjects (controls)2 by tertile of virus 
antibody measure in the controls
Virus and cancer group Control tertiles Cases/Controls OR 95% CI P-trend
HSV-1 and Oral cancer 0–5.04 23/200 1.00
5.05–6.07 26/199 1.06 (0.6 – 2.0)
6.08+ 31/199 1.28 (0.7 – 2.3) 0.40
HSV-2 and Cervical cancer 0–1.08 11/91 1.00
1.09–2.17 11/91 0.90 (0.4 – 2.2)
2.18+ 23/90 1.82 (0.8 – 4.1) 0.10
EBV-EBNA and non-Hodgkin lymphoma 0–3.81 24/208 1.00
3.82–5.29 31/203 1.32 (0.7 – 2.4)
5.30+ 22/211 0.87 (0.4 – 1.8) 0.80
EBV-EBNA and Hodgkin lymphoma 0–3.87 33/211 1.00
3.88–5.31 18/208 0.49 (0.3 – 0.96)
5.32+ 21/208 0.66 (0.3 – 1.4) 0.19
HHV-6 and Oral cancer 0–1.59 16/195 1.00
1.60–2.43 28/194 1.83 (0.9 – 3.6)
2.44+ 31/195 2.21 (1.1 – 4.3) 0.02
HHV-6 and Hodgkin lymphoma 0–1.58 21/172 1.00
(excluding oral cancers) 1.59–2.40 17/174 0.87 (0.4 – 1.7)
2.41+ 28/172 1.32 (0.7 – 2.5) 0.39
HHV-6 and Myeloid Leukaemia 0–1.61 47/131 1.00
(excluding oral cancers) 1.62–2.59 52/134 1.16 (0.7 – 1.9)
2.60+ 26/131 0.58 (0.3 – 1.0) 0.03
1For associations that had been reported previously.
2 The control group in these analyses included all other subjects, except patients with multiple myeloma, because in general mean antibody levels 
did not vary significantly across disease groups after exclusion of subjects with multiple myeloma (Figure 1), and including all patients increased the 
power of these analyses.
All analyses are adjusted for age group, sex, day of assay and assay plate.Infectious Agents and Cancer 2006, 1:2 http://www.infectagentscancer.com/content/1/1/2
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small sub-groups. However, our results suggest that high
IgG antibody measures against EBV-EBNA do not appear
to be relevant in most lymphomas in this population. Sev-
eral other associations between herpesviruses and cancers,
which have been reported less consistently in the litera-
ture, were not clearly evident in the current study includ-
ing: HSV-1 and oral cancer; HSV-2 and cervical cancer;
HHV-6 and Hodgkin lymphoma; and HHV-6 and mye-
loid leukaemia.
There was evidence of an increased risk of oral cancer for
subjects in the highest compared to lowest tertile of anti-
bodies against HHV-6 compared to other subjects (OR =
2.21, 95% CI 1.1 – 4.3), and a trend of increasing risk
across the tertiles (p = 0.02). A similar study in India of
patients with Hodgkin lymphoma, non-Hodgkin lym-
phoma, oral cancer and healthy controls found that
patients with oral cancers had elevated levels of HHV-6
antibodies compared to the healthy controls [7]. As far as
we are aware no additional studies have published results
on the association between HHV-6 and oral cancer, but
since two studies have found a positive relationship fur-
ther research is warranted. There was also an unexpected
small decrease in the risk of myeloid leukaemia in
patients with the highest tertile of antibodies against
HHV-6 (OR = 0.58, 95% CI 0.3 – 1.0). An increased risk
of acute myeloid leukaemia and HHV-6 has been reported
previously in some studies [6,14,15], although other stud-
ies have not found evidence of such an association
[16,17].
The retrospective design on this study means that it is pos-
sible that the cancer affected the patient's antibody levels
and therefore that the antibody levels reflect a conse-
Table 3: Mean log antibody measure (and standard error) for human herpesviruses 1–6 according to age at diagnosis, sex and other 
socio-demographic factors.
Risk factor Virus
HSV-1 HSV-2 VZV EBV-EBNA CMV HHV-6
Age <20 1.55 (0.11) -0.19 (0.20) 1.06 (0.12) 1.52 (0.15) 1.79 (0.21) 0.64 (0.15)
20–39 1.61 (0.04) 0.25 (0.08) 1.06 (0.05) 1.44 (0.07) 2.19 (0.12) 0.70 (0.06)
40–59 1.61 (0.04) 0.36 (0.07) 1.07 (0.05) 1.40 (0.07) 2.26 (0.07) 0.74 (0.06)
60+ 1.60 (0.05) 0.48 (0.08) 1.11 (0.06) 1.47 (0.07) 2.41 (0.09) 0.66 (0.05)
p-value 0.92 0.003 0.41 0.77 0.006 0.52
Sex Males 1.59 (0.05) 0.05 (0.08) 1.03 (0.06) 1.43 (0.07) 1.98 (0.09) 0.59 (0.06)
Females 1.60 (0.05) 0.40 (0.08) 1.11 (0.06) 1.48 (0.07) 2.34 (0.10) 0.78 (0.06)
p-value 0.91 <0.0001 0.09 0.44 <0.0001 0.0002
Smoking Never 1.60 (0.04) 0.21 (0.08) 1.03 (0.05) 1.45 (0.07) 2.16 (0.09) 0.67 (0.06)
Ever 1.59 (0.05) 0.24 (0.09) 1.11 (0.06) 1.46 (0.08) 2.17 (0.10) 0.70 (0.06)
p-value 0.91 0.56 0.07 0.96 0.94 0.34
Education < Grade 3 1.59 (0.05) 0.30 (0.09) 1.10 (0.06) 1.41 (0.08) 2.18 (0.10) 0.74 (0.07)
Grade 3–7 1.64 (0.05) 0.24 (0.08) 1.09 (0.05) 1.47 (0.07) 2.13 (0.09) 0.69 (0.06)
Grade 8+ 1.55 (0.05) 0.14 (0.09) 1.04 (0.06) 1.49 (0.08) 2.18 (0.10) 0.64 (0.07)
p-value 0.53 0.09 0.26 0.18 0.99 0.14
Area of birth Urban 1.61 (0.05) 0.28 (0.09) 1.10 (0.06) 1.46 (0.07) 2.14 (0.10) 0.70 (0.06)
Rural 1.57 (0.04) 0.18 (0.08) 1.05 (0.05) 1.45 (0.07) 2.19 (0.09) 0.67 (0.07)
p-value 0.29 0.13 0.16 0.67 0.48 0.45
Area living Urban 1.59 (0.04) 0.19 (0.07) 1.08 (0.05) 1.45 (0.07) 2.17 (0.09) 0.71 (0.06)
Rural 1.59 (0.05) 0.27 (0.09) 1.07 (0.06) 1.46 (0.08) 2.15 (0.11) 0.67 (0.06)
p-value 0.99 0.35 0.83 0.76 0.85 0.53
HIV +ve 1.53 (0.06) 0.27 (0.11) 1.12 (0.07) 1.43 (0.09) 2.22 (0.12) 0.71 (0.08)
-ve 1.66 (0.04) 0.18 (0.07) 1.02 (0.05) 1.48 (0.06) 2.11 (0.08) 0.67 (0.05)
p-value 0.03 0.35 0.10 0.52 0.34 0.66
No. of 0–2 1.60 (0.05) 0.12 (0.08) 1.02 (0.06) 1.47 (0.07) 2.12 (0.09) 0.64 (0.06)
sexual 3–5 1.58 (0.05) 0.25 (0.08) 1.05 (0.06) 1.41 (0.07) 2.18 (0.09) 0.75 (0.06)
partners 6+ 1.60 (0.05) 0.31 (0.09) 1.15 (0.06) 1.49 (0.08) 2.19 (0.11) 0.67 (0.07)
p-value 0.96 0.01 0.03 0.96 0.34 0.26
Marital Single 1.58 (0.04) 0.06 (0.08) 1.04 (0.05) 1.45 (0.07) 2.03 (0.09) 0.65 (0.06)
status Married 1.62 (0.05) 0.22 (0.08) 1.11 (0.05) 1.43 (0.07) 2.16 (0.09) 0.67 (0.06)
Widowed 1.59 (0.06) 0.20 (0.11) 1.04 (0.07) 1.41 (0.09) 2.17 (0.12) 0.66 (0.08)
Separated 1.58 (0.07) 0.42 (0.12) 1.10 (0.08) 1.54 (0.10) 2.29 (0.14) 0.77 (0.09)
p-value 0.64 0.005 0.45 0.52 0.26 0.34
Multivariate analysis of variance excluding patients with multiple myeloma and adjusted for all factors above plus disease group, plate and day of 
assay. P-values are for trend tests where appropriate and otherwise for heterogeneity.Infectious Agents and Cancer 2006, 1:2 http://www.infectagentscancer.com/content/1/1/2
Page 8 of 9
(page number not for citation purposes)
quence rather than a cause of the cancer. There was evi-
dence of this with respect to the multiple myeloma
patients, who had lower than average mean log antibody
measures for response to all six herpesviruses. This may be
because myeloma is an over-production of a single immu-
noglobulin class, which could in turn down-regulate pro-
duction of other immunoglobulins/antibodies. None of
the other disease groups had a systematically higher or
lower log antibody measures for response to all six of the
herpesviruses. However, it remains a possibility that the
positive association between raised HHV-6 antibody lev-
els and the risk of oral cancer could have been caused by
opportunistic reactivations due to cancer-associated
immunosuppression. Future studies should preferably be
conducted with prospectively collected blood samples.
Little is known about the determinants of infection with
and antibody response to herpesviruses 1–6 in the popu-
lation studied. In an analysis of associations with age, sex
and lifestyle factors there was evidence that, as expected,
HSV-2 antibody measures increased with increasing
number of sexual partners. In addition, antibody meas-
ures to both HSV-2 and CMV were significantly higher in
older age groups, presumably reflecting an increasing
number of re-infections, and in women. For HHV-6,
which is probably transmitted via saliva [18], antibody
measures were also found to be higher in women than in
men. Several other studies have reported similar findings
for HHV-6 [19,20] although in the study in West Africa
and the Caribbean, this was only true for children [19].
Primary HHV-6 acquisition has been found to be associ-
ated with female sex [21]. HIV positive patients in our
study did not have significantly higher average antibody
measures in response to any of these herpesviruses.
As quantitative methods have not previously been widely
used in epidemiological studies of herpesviruses we
included a quality control analysis to assess the repeata-
bility of the assay results. We found systematic variability
that could be attributed to differing laboratory conditions
and for HSV-1 and HSV-2 variability attributable to either
the binding of the assay components to the plates or cali-
bration control samples that were not effective at reducing
the variation between plates. For quantitative assessments
improvements to the kit techniques which we used are
needed, possibly using different antigens. In the current
study we randomised the patients' samples to the plates so
that the systematic differences will not have biased our
results and took account of these systematic sources of
variability in the analyses by adjusting for the plate and
day on which the assay was run.
Conclusion
In the black adult population of greater Johannesburg nei-
ther mean IgG antibody measure nor high antibody meas-
ures against human herpesvirsues 1 – 6 were strongly
associated with any of the seven selected cancer groups.
We do not think that the variability in the quantitative
assay results concealed any strong associations, but we
may not have had sufficient power to detect weak associ-
ations or associations with a sub-type of cancer. The find-
ing of a small increased risk for oral cancer with increased
antibodies to HHV-6 merits further exploration.
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